Toft Group Completes Executive Search for Retrophin (NASDAQ: RTRX) in San Diego, CA

Executive search firm Toft Group has placed Gayle Bresnahan as Associate Director, Clinical Operations at Retrophin in San Diego, CA. Ms. Bresnahan offers 20 years of clinical research within Oncology, Diabetes, Nephrology, Neurology and Infectious Disease therapeutic areas. She most recently served at Intercept Pharmaceuticals as Associate Director, Clinical Operations, where she was responsible for project management and execution of Phase II and III non-viral liver disease studies. Ms. Bresnahan received her BS in Business Administration from Bristol University.

About Retrophin

Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in additional rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Thiola®, Cholbam® and Chenodal®.

Toft Group Completes Executive Search for Ascendis Pharma Inc., (NASDAQ: ASND) in Palo Alto, CA

Executive search firm Toft Group has placed Dr. Aimee Shu as the Director, Clinical Development Endocrinology for Ascendis Pharma in Palo Alto, CA. Dr. Shu is a board-certified Endocrinologist who joins Ascendis from Stanford University where she served as Clinical Associate Professor of Medicine and Associate Program Director, Endocrinology Fellowship Training Program. She earned her MD from Harvard Medical School.

About Ascendis Pharma

Ascendis Pharma is applying the TransCon technology platform to build a leading rare disease commercial company. The company utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases by improving clinically validated parent drugs and creating therapies with potential for best-in-class efficacy, safety and/or convenience.

Ascendis Pharma has a wholly-owned pipeline of rare disease endocrinology programs, including once-weekly TransCon Growth Hormone, which is currently being evaluated in the Phase 3 heiGHt Trial for children with growth hormone deficiency (GHD), TransCon PTH, a long-acting prodrug of parathyroid hormone for hypoparathyroidism, and TransCon CNP, a long-acting prodrug of C-Type Natriuretic Peptide for achondroplasia. Additionally, Ascendis Pharma has multi-product collaborations with Sanofi in diabetes and Genentech in the field of ophthalmology.

Robin Toft, CEO of Toft Group Executive Search, 5-Time Finalist for Most Admired CEO Award

San Diego, CA – Toft Group, a top executive recruiting firm focusing exclusively on building leadership teams for Life Sciences and Healthcare companies, is proud to announce that President & CEO, Robin Toft, was named a finalist for the 2017 Most Admired CEO Award, in the category of Private Company by the San Diego Business Journal.

This presigious award recognizes San Diego business leaders’ significant achievements in innovation, financial success, philanthropic involvement, and employee empowerment within their companies and in the community. Nominees are judged in the categories of nonprofit organization, business nonprofit, education, family-owned business, government agency, privately held company and public company.

This is the 5th ‘Most Admired CEO’ finalist award for Toft, who was also recognized by the San Diego Business Journal as a “Women Who Mean Business” finalist two consecutive years. Mr. J. David Enloe, whom Toft Group placed as CEO of Ajinomoto Althea, Inc. won the award for the Private Company category that included over 200 employers.

“I am honored to be alongside such exceptional an incredible group of leaders in San Diego who are continuously improving our local economy,” commented Toft. “We are thrilled one of the executives in Toft Group’s network, David Enloe, was awarded and extend our congratulations to the outstanding recipients for their well-deserved awards.”

All finalists were recognized at a special ceremony on Thursday June 15th, 2017.

About Toft Group Executive Search

Toft Group Executive Search is “Changing the Future of Medicine, One Relationship at a Time” and we take pride in the fact that our work helps our clients accelerate getting novel products to market. Named a Top 150 Fastest Growing Private Company and a Top 50 Executive Search Firm in Life Sciences, we are a global retained executive search firm that is 100% dedicated to life sciences & healthcare industries.  Our customers include biotech, pharmaceutical, medical device, digital health, and diagnostic companies. With offices in San Francisco, San Diego and Boston, we assist a wide range of local, national and international companies – from venture backed start-ups to Fortune 500 corporations. For more information, visit www.thetoftgroup.com.

Toft Group Completes Executive Search for Greenwich Biosciences (NASDAQ: GWPH) in Carlsbad, CA

Executive search firm Toft Group has placed Mr. Jeff Krol as Vice President, Market Access at Greenwich Biosciences in Carlsbad, CA. Mr. Krol brings 25 years of experience in managed markets leadership. He most recently served with Avanir Pharmaceuticals as Executive Director, Managed Markets and Project Management, and previously served in the same company as Senior Director, Managed Markets. Mr. Krol earned his B.S. in Chemistry and Physics from The Ohio State University, and his M.S. in Education from the University of California, Berkeley.

About Greenwich Biosciences

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in 31 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy.

Toft Group Completes Executive Search for Muse Bioscience in Boulder, CO

Executive search firm Toft Group has placed Mr. Jason Amsbaugh as Senior Director, Marketing at Muse Bioscience in Boulder, CO. Mr. Amsbaugh brings over a decade of experience in marketing and product management in the industry to this new role. He most recently served as the Director of Global Marketing for ArcherDX, a NGS-based cancer diagnostic startup. Prior, he served with Thermo Fisher Scientific as a Product Portfolio Manager and early in his career held sales roles for industry leaders Abbott Molecular Diagnostics, Thermo Fisher Scientific, and VWR International. Mr. Amsbaugh earned his MBA from the University of Colorado, Boulder and BS degree from Colorado State University.

About Muse Bioscience

Muse bio is inspiring a new era of genome engineering that will transform our understanding of biology. Muse bio delivers power to researchers and production scientists in the field of genome engineering and synthetic biology through the combination of a powerful forward design software package, a proprietary benchtop biofoundry, and custom consumables and reagents. Its next-generation, CRISPR-based ForgeCraft technology dramatically improves and simplifies genome engineering.

Toft Group Completes Executive Search for Drawbridge Health in Menlo Park, CA

Executive search firm Toft Group has placed Mr. Lee McCracken as Chief Executive Officer at Drawbridge Health in Menlo Park, CA. Mr. McCracken is a C-level executive with over 20 years of pharmaceutical, biotech, diagnostics, and venture capital experience. He previously served as the Chief Executive Officer of Gensignia Life Sciences Inc., a privately held miRNA-digital IT company, where he was charged with developing strategy, establishing a clinical laboratory, and performing clinical studies for reimbursement. Prior to his role at Gensignia, Mr. McCracken was the President and Chief Executive Officer of Pathwork Diagnostics, Inc.. Mr. McCracken earned his B.S. in Commerce from Santa Clara University, his M.S. in Computer Science from the University of Dayton, and an MBA in Strategy/Venture Capital from the University of California, Los Angeles

About Drawbridge Health

Drawbridge Health is a medical technology company fusing the science of chemistry with the fundamentals of logistics to greatly improve the blood sampling process. Our mission is to power the shift in healthcare from being reactive to proactive, enabling predictive medicine to be realized by bridging diagnostic testing from sample to delivery to decision. This transformation begins with how we approach the collection and the interpretation of medical diagnostics tests – the data that we use to make nearly all of our medical decisions.

Toft Group Completes Executive Search for First Light Biosciences in Bedford, MA

Executive search firm Toft Group has placed Mr. Kevin Wyckoff as Vice President, Regulatory & Clinical Affairs in Bedford, MA. Mr. Wyckoff brings 25 years of diverse management experience to First Light in quality assurance and regulatory affairs. He most recently served with Roka Bioscience, a molecular diagnostics company, as the VP, Quality, Regulatory and Compliance, and previously served as the Director of Regulatory Affairs for Ortho Clinical Diagnostics. Mr. Wyckoff earned his B.S. in Chemistry from Louisiana State University, and his M.S. in Regulatory Sciences from Northeastern University.

About First Light Biosciences

First Light Biosciences is developing breakthrough automated medical diagnostic products for rapid, sensitive, and cost-effective detection of Healthcare Associated Infections (HAI). The products address the need for cost-effective and accurate diagnostics to meet the explosive growth in testing. New testing is being driven by clinical studies showing that testing for the infectious agents can help to dramatically lower the rate of hospital infections. Based on its proprietary MultiPath™ detection technology, First Light’s products combine the performance of the most advanced commercial laboratory tests with unprecedented affordability and ease-of-use.

Toft Group Completes Executive Search for Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) in Hercules, CA

Executive search firm Toft Group has placed Dr. Jaime Humara as Vice President, LSG Marketing at Bio-Rad Laboratories, Inc. in Hercules, CA. He most recently served with Beckman Coulter, a leading life sciences and diagnostics product company, as Director of Global Strategic Marketing, Molecular Diagnostics. Dr. Humara brings over a decade of experience in marketing and product development, having worked in multiple roles for Thermo Fisher Scientific (formerly Life Technologies), most recently as the Senior Director, North America Regional Marketing which included leading all marketing programs for Life Technologies branded products in North America, of which there were over 50,000. He earned his doctorate in Plant Biotechnology and BS degree from the University of Oviedo in Asturias, Spain.

About Bio-Rad

Bio-Rad Laboratories, Inc. develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The Company employs more than 8,250 people worldwide and had revenues exceeding $2 billion in 2016.

Toft Group Completes Executive Search for LabCorp (NYSE: LH) in Burlington, NC

Executive search firm Toft Group has placed Dr. Mary A. Williamson as the Vice President of Laboratory Operations at LabCorp in Burlington, NC. She is a senior laboratory leader offering 20+ years of clinical experience. She most recently served as the Vice President of Scientific Affairs & Laboratory Operations at ACM Global Central Laboratory in Rochester, NY. She holds a PhD and Master’s in Toxicology from the University of Rochester School of Medicine & Dentistry.

About LabCorp

Laboratory Corporation of America® Holdings (NYSE: LH), an S&P 500 company, is the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and develops technology-enabled solutions to change the way care is provided. With net revenue in excess of $8.5 billion in 2015, LabCorp’s 50,000 employees serve clients in 60 countries.

Toft Group Completes Chief Business Officer Search for GeneCentric Therapeutics in Durham, NC

GeneCentric Therapeutics, Inc., a precision medicine company dedicated to accelerating drug development by redefining the advanced classification of cancers, today announced the appointment of Walter M. Capone as Chief Business Officer. In his role as CBO, Mr. Capone will lead the expansion of pharmaceutical and biotech drug development collaborations involving GeneCentric’s Cancer Subtyping Platform (CSP™), and will oversee the company’s commercial strategy and growth.

“We are excited to have Walter join our strong leadership team,” said Chief Executive Officer Dr. Myla Lai-Goldman. “His expertise in drug development and commercialization will enable GeneCentric Therapeutics to actively expand its pharmaceutical and biotech company collaborations to advance therapeutic breakthroughs.”

Robin Toft, President and CEO of Toft Group said: “GeneCentric is a forward-thinking organization with an incredibly passionate leadership team. Walter will add great value to the organization, and will be a strong contributor to the continued growth of the company.”

Mr. Capone most recently served as CEO and President of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC), advancing industry, academic research, government agency and patient community collaborations to drive breakthroughs for patients. The launch of the landmark CoMMpassSM Study, support in advancing six new myeloma therapies to market, and expansion in innovative academic/industry partnerships were among his accomplishments. Prior to joining the MMRF, Mr. Capone had over 20 years of pharma/biotech leadership experience in the United States and internationally in the areas of oncology, immunology and infectious disease drug development and commercialization at Progenics Pharmaceuticals, Trimeris Inc., Triangle Pharmaceuticals, Bristol-Myers Squibb, Wyeth, and Lederle. He received his MBA from Columbia University Business School and BA from Brown University.

About Toft Group Executive Search

Toft Group Executive Search is “Changing the Future of Medicine, One Relationship at a Time” and we take pride in the fact that our work helps our clients accelerate getting novel products to market. We are a global retained executive search firm that is 100% dedicated to life sciences & healthcare industries. Our customers include biotech, pharmaceutical, medical device, digital health, and diagnostic companies. With offices in San Francisco, San Diego, and Boston, we assist a wide range of local, national and international companies – from venture backed start-ups to Fortune 500 corporations.

About GeneCentric

GeneCentric Therapeutics, Inc. is a privately-held precision medicine company that is redefining the advanced classification of cancers through the development and commercialization of its proprietary Cancer Subtype Platform (CSP™). By defining subtypes of cancer, CSP™ can enable drug developers to better predict drug response and determine why drugs fail in late stage clinical trials. GeneCentric creates and applies technologies focused on enhancing, accelerating and de-risking the costly drug development process to enable its industry partners to advance therapies which obtain the best possible patient treatment outcomes. GeneCentric was founded in 2011 and is based in Durham, NC. In addition to Bristol-Myers Squibb, its investors include Hatteras Venture Partners and Laboratory Corporation of America.